Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that epigallocatechin-3-gallate (EGCG) may reduce paclitaxel-induced apoptosis in human dermal papilla cells by regulating microRNA expression related to apoptosis and cell proliferation.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This study found that vitamin D regulates cholesterol metabolism and may influence prostate cancer development through mechanisms affecting prostate cell growth and sex hormone metabolism.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.

This review discusses the potential of plant polyphenols to overcome multidrug resistance in various solid cancers and reports no new experimental results; further research is suggested.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

This study found that prenatal exposure to finasteride in rats led to permanent changes in developmental endpoints like anogenital distance and nipple retention, which were predictive of further reproductive tract malformations.

This study indicated that while testosterone replacement in older men with low testosterone increases muscle mass and strength and reduces fat, its effects on physical function, disability, falls, or fractures remain unclear.

This review discusses recent data on the use of anabolic-androgenic steroids and other steroid compounds and reports no new clinical results.

This study found that early-onset male pattern baldness was associated with a reduced relative risk of prostate cancer.

This study found that resveratrol significantly alleviated testicular damage in male rats caused by finasteride, which otherwise led to decreased testosterone levels and various histopathological alterations in the testes.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This review discusses the structure and function of steroid nuclear receptors, particularly focusing on androgen receptor dysregulation in prostate cancer and androgen insensitivity syndromes, without reporting new experimental results.

This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This article reviews the care of transgender patients, encompassing diagnosis, treatment options, and challenges in health care access, but does not present new research findings; the authors emphasize the critical role of providers in addressing transgender health needs.

This article discusses the potential effects of exogenous testosterone, highlighting that its impact on prostate cancer progression, cardiovascular health, and behavior remains uncertain and needs further investigation.

This review discusses the association between androgen receptor CAG repeat polymorphism and several health conditions, including Kennedy’s disease and urologic disorders, without reporting new clinical results.

This study's model suggests that low androgen levels can increase selection for prostate cancer phenotypes resistant to hormonal therapy, potentially leading to more aggressive forms of cancer.

This study found that low-dose tamoxifen may effectively treat painful gynecomastia in patients receiving flutamide and finasteride for advanced prostate cancer.

This study suggests that 5α-reduced glucocorticoids may have anti-inflammatory potential and could serve as biomarkers for liver inflammation in metabolic disease, with implications for drug development.

The study observed that finasteride reduced fertility in male Sprague-Dawley rats by impairing the formation of copulatory plugs, an effect considered specific to rats and not applicable to species without this reproductive feature.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This review discusses the potential role of androgen receptor CAG repeat polymorphism testing in hypogonadism management for both sexes, but its clinical utility remains unclear and requires further investigation.

This study suggests that early onset androgenetic alopecia in men may indicate a male PCOS equivalent, possibly leading to higher risks of metabolic and cardiovascular disorders later in life.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This review discusses androgen manipulation strategies for conditions like benign prostatic hyperplasia and prostatic carcinoma but reports no new clinical results.